Limax Biosciences

Executive Summary

Limax Biosciences is a Cambridge-based biotechnology company pioneering advanced hydrogel tissue adhesives inspired by slug mucus. Its proprietary biomaterials are designed to strongly adhere to wet, dynamic surfaces both inside and outside the body, addressing critical unmet needs in surgical sealing, wound healing, and localized drug delivery. The lead product, HemoMax, is a hemostatic adhesive engineered to seal leaks, promote tissue repair, and enable targeted therapeutic release. Founded in 2020, Limax is positioned in the biologics and immunology sectors, leveraging a unique bioinspired approach to overcome limitations of current tissue adhesives, such as poor wet adhesion and lack of biocompatibility. The company is privately held with no disclosed funding, indicating early-stage development. As a preclinical-stage firm, Limax's value hinges on generating robust proof-of-concept data and securing partnerships or financing to advance HemoMax toward clinical trials. The competitive landscape includes established players like Ethicon and Cohera, but Limax's differentiation through biomimicry could offer superior performance in challenging surgical environments.

Upcoming Catalysts (preview)

• Q4 2026Preclinical data readout for HemoMax in relevant animal models70% success
• H1 2027Series A financing round to fund IND-enabling studies60% success
• 2028First-in-human trial initiation for HemoMax40% success